Eli Lilly targets alleged black market sales of its experimental GLP-1 drug

Summary

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide.  Lilly’s lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss “hack.”  Those entities falsely claim their drugs are for “research-use only” when…